Dr Lalchand. Lab (541299)

Score breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Reported profit grew 33.33% year-on-year, suggesting some cost control or operating leverage.
• Piotroski F-Score of 6/9 indicates moderately sound fundamentals across profitability, leverage, and efficiency.
• PEG ratio of 0.88 looks reasonable if the current earnings growth is sustainable.
• Small market cap of ₹12 Cr leaves theoretical room for upside if the business stabilizes and scales.

Concerns

• Sales declined 3.76%, and the latest quarter's net profit is ₹0 Cr, so recent earnings strength is not broad-based.
• ROCE of just 2.81% shows very poor returns on capital employed.
• P/E of 29.28 is rich for a company with shrinking revenue, zero dividend, and negligible reported profits.
• Book value, debt/equity, and promoter holding are unavailable, limiting confidence for a microcap investment.

AI Analysis

At ₹27.60, Dr Lalchand Lab carries a market cap of just ₹12 Cr — a microcap that would barely register on my radar. In the Buffett/Graham framework, the first question is always: what is the return on capital? Here, ROCE is only 2.81%, which tells me this business is not earning a satisfactory return on the money deployed. Sales have actually shrunk 3.76%, while reported profit jumped 33.33% — but with the latest quarter's net profit at ₹0 Cr, that growth is from a razor-thin or nonexistent base. A P/E of 29.28 for a company whose sales are falling and whose latest quarter shows no profit is not a margin of safety; it is a hope premium. The PEG ratio of 0.88 flatters only if that 33% profit growth is sustainable, and I see no evidence of that in declining sales. The Piotroski score of 6/9 is modestly supportive, but it does not compensate for weak returns and tiny scale. I cannot assess promoter holding or book value from the given data, which itself is a red flag: in a ₹12 Cr company, transparency matters enormously. There is no dividend to anchor the investor while waiting. This is not a wonderful business at a fair price; it is a troubled small-cap at a demanding multiple. The 52-week range of ₹8.87 to ₹28.70 shows a stock that has more than tripled — likely on hope rather than hard fundamentals. For a value investor, the prudent action is to wait on the sidelines until Dr Lalchand demonstrates consistent sales growth, improved ROCE, and real reported earnings. Without those, I cannot recommend ownership. In the end, a great investment requires an excellent business, not just a rising share price.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer